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Abstract
Objectives: Dysregulation of the hypothalamus-pituitary-adrenal (HPA) axis has frequently been reported in multiple
sclerosis (MS). So far, HPA axis function in MS has predominantly been studied under pharmacological stimulation which is
associated with a series of methodological caveats. Knowledge of circadian cortisol patterns and cortisol awakening
response (CAR) is still limited.
Methods: A total of 77 MS patients (55 relapsing-remitting MS (RRMS)/22 secondary-progressive MS (SPMS)) as well as 34
healthy control (HC) subjects were enrolled. Diurnal cortisol release was assessed by repeated salivary cortisol sampling.
Neurological disability was rated by the Kurtzke’s Expanded Disability Status Scale (EDSS). Depressive symptoms and
perceived stress were assessed by self-report measures.
Results: RRMS but not SPMS patients differed in circadian cortisol release from HC subjects. Differences in cortisol release
were restricted to CAR. Treated and treatment naı¨ve RRMS patients did not differ in CAR. In a RRMS follow-up cohort (nine
months follow-up), RRMS patients with EDSS progression ($0.5) expressed a significantly greater CAR compared to HC
subjects. RRMS patients with a stable EDSS did not differ from HC subjects. Neither depressive symptoms nor perceived
stress ratings were associated with CAR in RRMS patients. In a step-wise regression analysis, EDSS at baseline and CAR were
predictive of EDSS at follow-up (R2 = 67%) for RRMS patients.
Conclusions: Circadian cortisol release, in particular CAR, shows a course specific pattern with most pronounced release in
RRMS. There is also some evidence for greater CAR in RRMS patients with EDSS progression. As a consequence, CAR might
be of predictive value in terms of neurological disability in RRMS patients. The possible role of neuroendocrine-immune
interactions in MS pathogenesis is further discussed.
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Introduction
The cortisol awakening response (CAR) is a well described
phenomenon which is characterized by a pronounced increase of
cortisol within 20 to 30 minutes after awakening [1,2]. While the
precise mechanisms are still not entirely understood, CAR seems
to be controlled by limbic regions [3,4]. It is further modulated by
various factors such as genetic polymorphisms [5], stressful
experience [5,6,7], affective symptoms [6,8] and inflammatory
states [9]. Independently of the underlying modulating mecha-
nisms, an elevated CAR indicates a hyperactive hypothalamus-
pituitary-adrenal (HPA) axis with an increased diurnal cortisol
release.
A hyperactive HPA axis has often been reported in multiple
sclerosis (MS): in post mortem studies enlarged adrenals [10] as
well as increased activity of corticotropin-releasing-hormone
(CRH) producing cells within the hypothalamus have been found
[11]. In response to intravenous administration of CRH, cortisol
release was increased in MS patients compared to healthy control
subjects [12,13]. HPA axis function also seems to be linked to
radiological as well as clinical aspects: increased cortisol response
to CRH was associated with gadolinium enhancing lesions, a
marker for acute central nervous system inflammation in MS [14].
In a three year follow-up study, increased adrenocorticotropic
hormone (ACTH) response to CRH administration has been
linked to disease progression and cognitive dysfunction [15]. A
series of most recent studies indicates a complex interaction
between depressive symptoms and diurnal cortisol release patterns
in MS [16,17].
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So far, most insights into HPA axis function in MS are based on
pharmacological and rather unphysiological interventions such as
the administration of CRH and/or dexamethasone (Dex). Testing
for HPA axis function under pharmacological conditions involves
invasive methods (e.g. intravenous injections, repeated blood
sampling) and is predominantly performed in a hospital setting.
Both factors are capable of inducing a considerable amount of
stress which by itself could possibly modulate cortisol release in
response to the pharmacological challenge.
Knowledge of HPA axis function in MS under non-stimulated
conditions is still limited [18] and data on diurnal cortisol release
patterns including CAR in a non-hospitalized setting are rare
[16,17].
In the current study, we measured diurnal cortisol release
including CAR under basal conditions in the absence of any
pharmacological stimulation. Saliva cortisol sampling was the
method of choice in order to allow for repeated, non-invasive
sampling in patients’ home environment. We hypothesize that MS
patients express an elevated diurnal cortisol release when
compared to healthy control (HC) subjects. Relapsing-remitting
(RRMS) as well as secondary-progressive (SPMS) MS patients
were studied in order to identify a possible link between circadian
cortisol release patterns and disease course as well as disease
duration. Finally, we expected diurnal cortisol patterns to be
associated with treatment [19], disease progression [15], affective
symptoms [16,17] and perceived stressful experience [6].
Methods
Participants
Eighty-six patients with definite MS according to revised
McDonald criteria [20] as well as thirty-seven HC subjects were
enrolled. A total of twelve participants (nine MS and three HC
subjects) had to be excluded from data analysis due to incomplete
cortisol profiles. The final sample consisted of fifty-five RRMS
patients, twenty-two SPMS patients and thirty-four HC subjects.
At study entry, a total of eighteen RRMS patients had never
received any form of MS disease modifying treatment (DMT)
(RRMS naı¨ve) so far. Twenty-six RRMS patients were studied
over a follow-up period (RRMS follow-up) (figure 1 & 2).
Characteristics of MS patients and HC subjects are listed in table 1.
Neurological and Psychometric Measures
For MS patients, neurological impairment was rated using
Kurtzke’s Expanded Disability Status Scale (EDSS) [21] based on
the Neurostatus scoring system (www.neurostatus.net). EDSS
ratings were performed by certified neurologists who have
previously performed rater trainings to minimized inter-rater
variability. Neurologists were blinded for information on HPA axis
function and psychometric measures. Depressive symptoms were
assessed by self-report measures (Center for Epidemiological
Studies Depression (CES-D) Scale) [22,23]. Perceived stress (past
three months, screening scale) was assessed by the Trier Inventory
for Chronic Stress (TICS) [24]. Self-report measures were received
at baseline.
Study Procedure
Participants were enrolled in two separate studies. Study I was a
cross-sectional study which involved a single visit at the local MS
centre. EDSS ratings were performed during this visit. Study II
was a follow-up study which involved a total of four visits. For
patients in study II, EDSS ratings were performed at the time of
the initial visit as well as nine months after the initial visit. As a
consequence, each MS patient received an EDSS rating at study
entry (study I & study II). A total of twenty-six RRMS patients
received two EDSS ratings over a period of on average nine
months (mean 9.00 months/standard deviation (SD) 0.75) (study
II). Please see figure 1 & 2 for illustration.
Exclusion criteria for MS patients (study I & II) were: inability
(physical/cognitive) to follow the study procedure, age .60 years,
steroid treatment within four weeks prior to study entry,
pregnancy, acute or chronic bacterial/viral infection. Exclusion
criteria for HC subjects (study I & II) were: MS diagnosis, a
diagnosis of any other neurological or autoimmune disorder, age
.60 years, steroid treatment, existence of any chronic inflamma-
tory disorder, pregnancy, acute or chronic bacterial/viral infec-
tion.
Study protocols were reviewed and approved by the local ethics
committee (Ethics Committee at the Technische Universita¨t
Dresden, Faculty of Medicine). All patients gave written informed
consent prior to study entry.
Cortisol Sampling
At the time of the initial visit, all participants were instructed to
collect salivary cortisol samples on two separate days within a
period of two weeks. Repeated sampling was performed in order
to obtain a more reliable measure from each participant. Patients
and HC subjects were equipped with two sets of SalivettesH
(Sarstedt, Nu¨mbrecht, Germany). Each participant was instructed to
collect saliva samples on six points in time over the day at the
home environment. In order to assess CAR, four measurements
were taken within the first hour after awakening (awakening, 30
minutes, 45 minutes, and 60 minutes after awakening). Additional
samples were collected at 3 pm and at 10 pm.
In order to avoid contamination with non-saliva fluid, solid
particles or blood, all participants were instructed to refrain from
eating, drinking or brushing their teeth prior to sampling. Patients
on DMT were asked to keep an interval of 12 hours between the
last DMT administration and saliva sampling. Collected samples
were kept refrigerated at minus 20uCelsius until analysis. Cortisol
concentrations were determined using a commercial luminescence
immuno assay (LIA) (IBL, Hamburg, Germany) with an inter-assay
coefficient of less than 5% and an intra-assay coefficient of less
than 4%.
Statistical Analysis
Statistical analysis was performed with Statistical Package for
Social Sciences (SPSS (IBM), Version 19.0 for Windows).
In order to increase reliability, each participant’s average
diurnal cortisol curve was calculated based on two separate
profiles. For CAR (samples 1–4), an area under the curve with
respect to ground (AUCawakening) was calculated as previously
described [25].
Group differences for saliva cortisol values were analyzed using
ANOVAs with repeated measures. Group differences for depres-
sive symptoms, neurological disability, and AUCawakening were
analyzed using ANOVA with post-hoc tests (Bonferroni) or two
tailed t-tests. Equal distribution of gender across groups was tested
by the Chi2 test. Correlation analyses were performed with
Pearson’s correlation.
Results
Circadian Cortisol Release and Disease Course
Groups were sex-matched (Chi2 test: p.0.05) but SPMS patients
were significantly older than RRMS patients (ANOVA, post-hoc:
p = 0.03) and HC subjects (ANOVA, post-hoc: p = 0.01). Age was
therefore considered as a covariate in the following analysis:
Cortisol Awakening Response in MS
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Circadian cortisol release significantly differed between groups
(ANOVA with repeated measures: main effect group: F = 4.36, p = 0.015)
(figure 3a) and was most pronounced in RRMS patients (age effect
time 6 age: F = 0.65, p.0.05; main effect age: F = 0.18, p.0.05).
Differences in cortisol release between groups were restricted to
CAR. Accordingly, RRMS patients showed a significantly greater
AUCawakening than HC subjects (ANOVA, post-hoc: p = 0.023). In
contrast, SPMS patients did not differ in AUCawakening from
RRMS patients (ANOVA, post-hoc: p.0.05) or HC subjects
(ANOVA, post-hoc: p.0.05) (figure 3a, table 2).
SPMS patients, but not RRMS patients showed a positive
association between AUCawakening and EDSS ratings (baseline)
(table 3). AUCawakening was not associated with disease duration in
either group (table 3).
MS patients reported significantly more depressive symptoms
than HC subjects (ANOVA, post hoc: RRMS.HC, p = 0.003;
SPMS.HC, p = 0.023) while RRMS and SPMS patients did not
differ in depressive symptom load (ANOVA, post-hoc: p.0.05)
(table 2). Depressive symptoms were not associated with
AUCawakening in RRMS or SPMS patients (table 3). MS patients
and HC subjects did not differ in perceived stress over the past
three months (ANOVA: p.0.05) (table 2). Perceived stress was not
associated with AUCawakening in RRMS patients. However, in
SPMS patients, AUCawakening was associated with perceived stress
(table 3).
Circadian Cortisol Release in Treated vs. Treatment Naı¨ve
RRMS Patients
In order to test whether circadian cortisol release is modulated
by DMT, we compared cortisol profiles from currently (or
previously) treated and treatment naı¨ve RRMS patients as well
as HC subjects. Groups were matched with respect to age
(ANOVA: p.0.05) and gender distribution (Chi2 test: p.0.05).
Circadian cortisol release significantly differed between groups
(ANOVA with repeated measures: main effect group: F = 3.58, p = 0.032)
(figure 3b). Differences were restricted to CAR. Accordingly,
treated RRMS patients expressed a significantly greater AUCawa-
kening when compared to HC subjects (ANOVA, post-hoc test:
p = 0.027). RRMS naı¨ve patients did not significantly differ from
treated RRMS patients or from HC subjects (ANOVA, post-hoc:
p.0.05) (table 2, figure 3a).
Figure 1. Sample description.
doi:10.1371/journal.pone.0060647.g001
Figure 2. Study design.
doi:10.1371/journal.pone.0060647.g002
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Groups significantly differed in EDSS at baseline (two-tailed t-test:
treated RRMS.RRMS naı¨ve, p = 0.003) and disease duration (two-
tailed t-test: treated RRMS.RRMS naı¨ve, p,0.001). However,
AUCawakening was not associated with EDSS ratings or disease
duration in either group (table 3). AUCawakening was not associated
with depressive symptoms or perceived stress in treated or
treatment naı¨ve RRMS patients (table 3).
Circadian Cortisol Release in a RRMS Follow-up Cohort
EDSS progression was calculated based on the difference in
EDSS at baseline and follow-up. Based on the EDSS difference,
RRMS patients were divided into one progression group (EDSS
progression $0.5) (N = 9) and into one stable group (EDSS
progression #0) (N = 17) (table 1).
The two groups were matched according to age (ANOVA:
p.0.05) and gender (Chi2 test: p.0.05) and did not differ in disease
duration, EDSS at baseline or length of follow-up period (all two-
tailed t-test: p.0.05). Although groups differed in frequency of
immune modulating treatment (table 1), these differences were not
statistically significant (Chi2 = 9.57, p.0.05).
Over the follow-up period, EDSS ratings showed a significantly
different pattern in the progression vs. non-progression group (time
6 group interaction: F = 57.92, p,0.001).
Groups significantly differed in terms of circadian cortisol
release (ANOVA with repeated measures: main effect group: F = 3.77,
p = 0.029; time 6 group interaction: F = 3.42, p = 0.006) (figure 3c).
Differences were restricted to CAR and RRMS patients with an
EDSS progression of $0.5 expressed a significantly more
pronounced AUCawakening than HC subjects (ANOVA, post-hoc:
p = 0.025). RRMS patients with stable EDSS levels did not differ
in AUCawakening from HC subjects (ANOVA, post-hoc: p.0.05)
(table 2, figure 3c). AUCawakening was not associated with
depressive symptoms or perceived stress in RRMS patients with
stable or progressive EDSS (table 3).
Finally, we performed a stepwise linear regression analysis with
EDSS at baseline and AUCawakening as predictors for EDSS at
follow-up.
Both variables significantly contributed to the model (EDSS at
baseline: ß = 0.65, p,0.001; AUCawakening: ß = 0.35, p = 0.011) and
explained 67% of the total variance (R2 = 0.67). In our model,
EDSS at baseline explained 56% of variance. Adding AUCawaken-
ing to the model explained for an additional 11%.
Discussion
Although there have been several studies on HPA axis function
in MS, to the best of our knowledge, this study is the first showing
course specific differences in circadian HPA axis function
including CAR.
Our data indicates that RRMS patients but not SPMS patients
express a significantly greater CAR when compared to age and sex
matched HC subjects. We were also able to show that these
changes in CAR cannot be primarily explained by treatment
effects or disease duration. Moreover, in a subgroup of RRMS
patients, greater progression in neurological disability over a nine
month follow-up period was associated with significantly greater
CAR compared to HC subjects. We were also able to show, that
the EDSS score at baseline in combination with CAR, was
reasonably predictive of EDSS after nine months.
Feedback Regulation versus Circadian HPA Axis Function
Elevated levels of ACTH and cortisol in response to CRH
administration in MS patients have frequently been reported
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Figure 3. Mean circadian saliva cortisol and AUCawakening. a) RRMS/SPMS patients and HC subjects b) treated RRMS/treatment naive RRMS
patients and HC subjects c) RRMS with stable EDSS/RRMS with EDSS progression $0.5 and HC subjects. Error bars reflect standard error of the mean.
Significant results are marked (*reflects p,0.05).
doi:10.1371/journal.pone.0060647.g003
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[13,14,26] and endocrine changes seem to be associated with
clinical course as well as disease progression.
In a recent study, increased 24 hour free urinary cortisol as well
as increased plasma morning cortisol levels (one time measure-
ment between 8 am and 10 am) were shown in a relatively large
cohort of MS patients [18]. HPA axis activity was most
pronounced in RRMS patients during acute relapse. Clinically
stable RRMS patients expressed intermediate levels while SPMS
patients expressed only moderately elevated circadian cortisol
levels [18]. Interestingly, patterns reported by Yssraelit and
colleagues significantly differ from course specific patterns that
are based on the Dex/CRH test [12] - an effect that could possibly
be explained by methodological differences in HPA axis testing:
while circadian regulation reflects an inherent release pattern that
is most likely under the control of central structures such as the
hippocampal formation [3,4], the combined Dex/CRH test
reflects an unphysiological stimulation protocol that was designed
to test for feedback regulation on hypothalamic as well as pituitary
levels. Thus, the Dex/CRH test and circadian cortisol levels reflect
two very distinctively regulated aspects of the same endocrine
system. In the light of the here presented data, we now have reason
to believe, that in MS, circadian function and feedback regulation
follow a unique course specific pattern in a way that feedback
regulation is most disturbed in progressive disease courses such as
SPMS and PPMS [12]. In contrast, circadian abnormalities seem
to be less pronounced [18] or non-existent in SPMS patients.
Here, RRMS patients, especially when in a clinically active state
(e.g. acute relapse, progression in neurological disability), show
most pronounced differences in circadian cortisol release. Inter-
estingly, disease progression but not current EDSS or disease
duration was associated with CAR in RRMS. This finding
indicates that circadian cortisol response is predominantly affected
by the acute disease state and not so much by previously
accumulated deficits and disease duration per se.
Treatment Effects and Circadian HPA Axis Function
Acute administration of Interferon-b (INF- b) has shown to cause
significant changes in cortisol release within MS patients [19] and
HC subjects [27]. It is therefore possible that HPA axis abnormal-
ities seen in MS could be explained by treatment effects. What holds
against this hypothesis is the fact that pronounced HPA axis
abnormalities have been observed in a large group of untreated MS
patients [18]. Also, HPA axis function seems to adapt to continuous
INF-b administration in a way that cortisol levels normalize over the
course of prolonged treatment (e.g. three months, one year) [19]
[27]. In our study, treated RRMS patients and treatment naı¨ve
RRMS patients did not significantly differ in AUCawakening which
further supports the hypothesis that circadian HPA axis changes
cannot be exclusively explained by treatment effects.
Perceived Stress, Affective Symptoms and Circadian HPA
Axis Function
An increased CAR [16] as well as increased evening cortisol
levels [17] have been described in MS patients with depressive
symptoms and in non-MS cohorts [28,29]. In contrast to these
previous findings, our data did not reveal such an association.
RRMS and SPMS patients reported significantly more depressive
symptoms compared to HC subjects but overall depressive ratings
were comparatively low and not clinically significant. We therefore
conclude that course specific circadian HPA axis differences exist
in the absence of clinically relevant depressive symptoms.
However, in regard of previous findings [16,17] we cannot rule
out that more severe depressive symptoms potentially modulate
circadian HPA axis function in MS patients.
MS patients (SPMS and RRMS) reported higher levels of
perceived stress but mean T-scores were within a normal range
and ratings did not significantly differ from HC subjects.
Moreover, increased AUCawakening in RRMS patients was not
associated with perceived stress. Our data therefore indicate, that
the observed differences in circadian HPA axis function in RRMS
patients cannot be primarily explained by psychological factors
such as perceived stress.
Interestingly, only in SPMS patients, AUCawakening was
positively associated with neurological disability and negatively
associated with perceived stress, which indicates that circadian
HPA axis function is more closely linked to neurological as well as
psychological aspects in more advanced disease stages. Further
studies are needed to elucidate the exact nature of this association.
Limitations
Our study was not without limitations. While the overall sample
size was quite reasonable, our follow-up cohort was comparatively
small and EDSS progression was only studied over a relatively
short period of nine months. As a consequence, the EDSS increase
in the progression group was relatively small and could potentially
be biased by inter-rater variability. Nonetheless, larger cohorts as
well as longer follow-up periods seem necessary to further
investigate the possible role of circadian HPA axis abnormalities
in disease progression.
Overall depressive symptoms in our cohort where rather mild
which could reflect a recruitment bias. Thus, further studies should
Table 3. This table lists correlations coefficients for the association between AUCawakening on the one hand and EDSS (baseline &
follow-up), disease duration, self-reported depressive symptoms and perceived stress (TICS screening scale) on the other hand.
Correlation for AUCawakening RRMS total group
RRMS currently or previously
on DMT RRMS naı¨ve RRMS follow-up total SPMS
N 55 37 18 26 22
EDSS baseline 0.09 0.12 20.22 0.29 0.46*
EDSS follow-up – – – 0.54** –
disease duration 0.09 0.01 0.38 0.19 0.02
depressive symptoms 0.02 0.09 20.24 0.11 20.13
stress ratings 20.02 0.09 20.27 0.11 20.48*
Correlation coefficients are displayed for RRMS patients (total group, RRMS naı¨ve, RRMS follow-up) and SPMS patients. Pearson’s correlation coefficients are displayed.
Significant results are marked (*p,0.05; **p#0.01).
doi:10.1371/journal.pone.0060647.t003
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specifically address circadian HPA axis function in subgroups of
more severely depressed patients.
Future Perspective on Neuroendocrine-immune
Interaction in MS
The HPA axis and the immune system interact on multiple levels.
It is a well- established finding, that a series of proinflammatory
cytokines can activate the HPA axis [30]. Based on their findings,
Besedovsky and del Rey suggested the existence of an immunoreg-
ulatory cytokine HPA axis circuit that plays an important role in the
central control of systemic inflammation [30]. Within such a circuit,
glucocorticoids (GC) have shown to inhibit the production of
proinflammatory cytokines by inhibiting the nuclear transcription
factor kappa B [31]. GC have also shown to influence a series of
immunological functions that are associated with MS pathology
such as Th1/Th2 balance [32], phospholipase A2 function [33] as
well as the production reactive oxygen species [34]. MS is an
inflammatory disorder and inflammation seems to be most
pronounced during the relapsing-remitting course of the disease
[35]. Accordingly, increased levels of proinflammatory cytokines
have been reported in clinically active RRMS patients [18].
Increased circadian HPA axis activation in RRMS patients
could therefore reflect a compensatory mechanism in response to
increased central as well as systemic inflammation. This interpre-
tation is in line with our finding that only RRMS patients with
EDSS progression but not stable RRMS patients expressed a
significantly greater CAR when compared to HC subjects. In
order to test this hypothesis, further studies on circadian HPA axis
function that also incorporate measures of GC effects on target
tissues (e.g. GC sensitivity on immune cells) seem mandatory.
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